Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes

Author： Garbino Jorge   Markham Lydia   Matulionyte Raimonda   Rives Vincent   Lew Daniel  

Publisher： Informa Healthcare

ISSN： 0036-5548

Source： Scandinavian Journal of Infectious Diseases, Vol.38, Iss.2, 2006-07, pp. : 110-113

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda

By Mueller Y.   Nguimfack A.   Cavailler P.   Couffignal S.   Rwakimari J. B.   Loutan L.   Chappuis F.  

Annals of Tropical Medicine and Parasitology, Vol. 102, Iss. 1, 2008-01 ,pp. : 11-19

Maney Publishing

Access to resources Recommend Favorite

The current role of amphotericin B lipid complex in managing systemic fungal infections

By Chu Patrick   Sadullah Shalal  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 3011-3020

Informa Healthcare

Access to resources Recommend Favorite

Biliary excretion of amphotericin B deoxycholate and amphotericin B lipid complex

By Duflo Frédéric   Allaouchiche Bernard   Chassard Dominique  

Scandinavian Journal of Infectious Diseases, Vol. 32, Iss. 5, 2000-11 ,pp. : 581-581

Informa Healthcare

Access to resources Recommend Favorite

Amphotericin B deoxycholate nasal spray administered to hematopoietic stem cell recipients with prior fungal colonization of the upper airway passages is associated with low rates of invasive fungal infection

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 17, Iss. 1, 2015-02 ,pp. : 1-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Should We Continue to Use the Cockcroft-Gault Formula?

By  

Nephron Clin Pract, Vol. 116, Iss. 3, 2010-07 ,pp. : c172-c186

Karger

Access to resources Recommend Favorite